Philip Morris International Inc (PM) earns a Roarable Rating of A- (Buy) with 81/100 RQD Confidence. High-quality cash engine (67% profit margin, 45% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, Philip Morris International Inc (NYSE: PM) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $208.79 (+0.14% 1D, market cap $324.98B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, PM ranks #12 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), PM carries a Roarable A- (81/100 RQD), trailing P/E of 28.6x, gross margin of 67.1%, and ROIC of 45.3%. By comparison, BTI (British American Tobacco Industries p.l.c. ADR) holds a C+ grade (66/100 RQD, P/E 32.8x, ROIC 9.9%, cap $131.93B) and MO (Altria Group Inc.) posts a A grade (89/100 RQD, P/E 18.4x, ROIC 48.4%, cap $128.15B). Among the 5-stock peer group, MO leads on earnings multiple (18.4x) while MO leads on capital efficiency (48.4% ROIC).
Per PM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001413329), Philip Morris International Inc generated $40.65B in revenue (+7.3% YoY), $11.35B in net income, and $10.66B in free cash flow against $69.19B in total assets and $34.75B in total debt. Key quantitative strengths: Strong cash generator (67% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±5.6% realized swing band)
SEC XBRL FY 2025 (10-K): 26.2% FCF Margin ($10.66B FCF) & 67.1% Gross Margin
Cannibal Buyback (-2.08% YoY Shares) & executive Form 4 sales trim 5 pts from alignment
Even with a 81/100 (A-) score, PM faces multiple-compression risk if 28.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.6% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($194.89) or 200D SMA ($182.24) invalidates the momentum regime and cuts Target Base ($230.40) toward Bear Floor ($171.21).
Philip Morris International Inc (PM) advanced +0.14% to $208.79, trading at 92% of its 52-week range ($142.11 – $214.35). High-quality cash engine (67% profit margin, 45% return on capital) with steady institutional support.
Yahoo Finance report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
WSJ report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Reuters report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
24/7 Wall St. report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Five income stocks cleared a rare filter this year: every single one raised its dividend payout, even as interest rates punished yield hunters. Find out which names backed those raises with data-center contracts, smoke-f
“Too big to fail” is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new so
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Philip Morris International Inc (PM) ranks #12 by composite RQD confidence (81/100, grade A-) and #6 by equity capitalization ($324.98B). Within this direct 5-issuer industry benchmark cohort, MO leads on earnings valuation at 18.4x trailing P/E, while MO leads on capital efficiency and profitability with 48.4% ROIC and 62.5% gross margin. MO currently holds the highest overall quantitative score in the immediate peer group at 89/100 (A) compared with PM at 81/100 (A-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PM
ACTIVE
Philip Morris International Inc | A- | 81/100 | 28.6x | 67.1% | 45.3% | +0.14% | $324.98B | Benchmark Subject |
| BTI British American Tobacco Industries p.l.c. ADR | C+ | 66/100 | 32.8x | — | 9.9% | +0.74% | $131.93B | /bti-vs-pm → |
| MO Altria Group Inc. | A | 89/100 | 18.4x | 62.5% | 48.4% | +1.67% | $128.15B | /mo-vs-pm → |
| DFTX Definium Therapeutics Inc. | D+ | 52/100 | — | — | -32.2% | -4.29% | $5.10B | /dftx-vs-pm → |
| RGC Regencell Bioscience Holdings Limited | D- | 38/100 | — | — | — | -2.19% | $3.40B | /rgc-vs-pm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Philip Morris International Inc (PM) reported GAAP revenue of $40.65B (+7.3% vs. FY2024 revenue of $37.88B , and +15.6% cumulative change since FY2023) , GAAP net income of $11.35B, operating cash flow of $12.23B, and free cash flow of $10.66B (-1.0% YoY). On the balance sheet, PM closed FY2025 with $69.19B in total assets against $34.75B in total debt (Altman Z-Score: 4.52, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.65B | $11.35B | $12.23B | $10.66B | $69.19B | $34.75B |
| FY2024 (FY) | 2024-12-31 | $37.88B | $7.06B | $12.22B | $10.77B | $61.78B | $32.24B |
| FY2023 (FY) | 2023-12-31 | $35.17B | $7.81B | $9.20B | $7.62B | $178.74B | $41.82B |
As of 2026-11-02, Philip Morris International Inc (NYSE: PM) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $208.79 (+0.14% 1D, market cap $324.98B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, PM ranks #12 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), PM carries a Roarable A- (81/100 RQD), trailing P/E of 28.6x, gross margin of 67.1%, and ROIC of 45.3%. By comparison, BTI (British American Tobacco Industries p.l.c. ADR) holds a C+ grade (66/100 RQD, P/E 32.8x, ROIC 9.9%, cap $131.93B) and MO (Altria Group Inc.) posts a A grade (89/100 RQD, P/E 18.4x, ROIC 48.4%, cap $128.15B). Among the 5-stock peer group, MO leads on earnings multiple (18.4x) while MO leads on capital efficiency (48.4% ROIC).
Per PM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001413329), Philip Morris International Inc generated $40.65B in revenue (+7.3% YoY), $11.35B in net income, and $10.66B in free cash flow against $69.19B in total assets and $34.75B in total debt. Key quantitative strengths: Strong cash generator (67% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
PM last traded at $208.79 (+0.14% on volume of 4,591,343 shares), positioning the stock +7.13% above its 50-day simple moving average ($194.89) and +14.57% above its 200-day simple moving average ($182.24). Across its 52-week range of $142.11 to $214.35, PM sits at the 92.3% percentile with a 14-day RSI of 63.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.6% ($197.10 to $220.48).
Why PM Stock advanced +0.14% Today — RQD Quant Desk Flash. High-quality cash engine (67% profit margin, 45% return on capital) with steady institutional support.
Per the Roarable RQD rating, PM carries an RQD Score of 81 and a letter grade of A-, with the verdict label "Roarable Buy — Superior Risk/Reward." The five pillars are:
Taken together, the scores indicate strength across cash generation, institutional interest, and balance sheet, with insider conviction the relatively weaker pillar. Upside drivers implied by the data include the high ROIC and institutional flow; the main valuation tradeoff is that P/E (TTM) of 28.6 and EV/EBITDA of 21.7 are elevated relative to the FCF yield of 3.28%.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $40648.0M | $14892.0M | $11348.0M | N/A | $10664.0M | $4872.0M | $34745.8M |
| FY 2024 | $37878.0M | $13402.0M | $7057.0M | N/A | $10773.0M | $4216.0M | $32244.3M |
| FY 2023 | $35174.0M | $11556.0M | $7813.0M | N/A | $7621.2M | N/A | $41824.9M |
Per the SEC financials, revenue rose from $35174.0M (FY 2023) to $40648.0M (FY 2025), and operating income rose from $11556.0M to $14892.0M over the same span. Per the market data, gross margin is 67.1%, operating margin 36.6%, and net margin 27.9%. Per the RQD rating, the Altman Z-Score is 4.52 and the Piotroski F-Score is 8/9. Debt declined from $41824.9M (FY 2023) to $34745.8M (FY 2025). FY 2023 net income of $7813.0M is higher than FY 2024's $7057.0M, while FY 2025 net income is $11348.0M.
The Risk Watch item on conflict-related cost pressure is the most significant negative signal in the feed. Catalyst items center on dividend growth and smoke-free revenue. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Philip Morris International Inc (PM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
WSJ report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Reuters report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
24/7 Wall St. report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Philip Morris International Inc (PM) market action, institutional positioning, and fundamental catalysts.
Welcome to the PM (Philip Morris International Inc) Roar Pit. Current RQD Composite is 81/100 (Roarable Buy — Superior Risk/Reward) in Medicinal Chemicals and Botanical Products. Bulls point to capital efficiency (45.3% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PM, but look at what you are paying: 28.6x trailing P/E with 67.1% gross margins. Unless Philip Morris International Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PM, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $208.50 (52-wk range $142.11 - $214.35), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).